isn't that something??
grhcgd, with the amount of time you are spending typing #$%$ about this NOTHAPPENING deal, you should be careful about carpal syndrome. you better sell your vrx while you have time. it is going to dip down pretty fast when it becomes clear that the deal will not happen. I am 110% sure pearson is already looking for his next target to play this game again.
whats up with vrx now?? going steadily higher?? I think you should ask that to the other ceo too while you are asking questions. Dont think vrx is even capabel of doing this deal now with the price trending lower and lower and the downgrades etc. All this did was bring agn out into the limelight for future investors.
see this is a diagnostic company and not a biotech. The data collection is not the issue it is the analysis which is in question here and that IMO is the most significant aspect of our product. I wanted to know whether they had questioned the statistical analysis methodology to arrive at the sensitivity %. I do however agree that the values from normal individuals will not be very critical since it is the sensitivity. For example among the 100 new samples to be tested, given the high sensitivity (97%) and low specificity the appy1 could potentially flag a very small percentage of them as positive for appendicitis (false positives). Obviously the number of false positives should be negligible and should fall within the reported levels.
quant, I think it is a strong investment for the future. tending low for now due to rebalancing and possible profit taking by few. significant positive trend in the future for sure.
we are 33c below the $2 mark. I guess at this point with lack of enough clarity regarding FDA query and response and release date the low price is justified. Longs what do you think?
roche already has pretty good deal with cris. why do you think they will need to buyout cris? I dont even see a remote possibility of that happening. Unless ofcourse any new pipeline shows good results which obviously is a bit far away. I think most of us will be holding this one for some time before it takes off.
I am surprised that we did not have results of normal individuals!! for comparison. Also with regards to diagnostic tests like appy1 analysis of the results is most critical. Do you think (from what Lundy said) that the analysis will reveal anything other (negative) than what they had previously reported?
resubmitting in Q4 of this year???? is this true?? so was the analysis of sensitivity flawed?? long timers pls comment if you listened to the talk.
those who heard the talk pls update. All I could get was from the twitter feed "issues with the analytical method and labeling". That is pretty serious as far as I am concerned but anybody who heard the talk pls comment. Also what is this talk about appy2?
well not an expert but could be because certain large volume buyers look for listing in these index before taking positions? so potentially many could be keeping off for now til good trustworthy news about current trials are released.
Instead of a press release he is doing a conf on business update "including" status of appy. We cannot assume anything at this point. If it was positive why not just a press release? However, as somebody previously said if the FDA query was very significant like more testing or data etc they should have informed us earlier. GLTA
I think it is valued healthy at this point. It is not pumped price. If it were pumped on "future prospects" it should have rested somewhere in the 4s. Now the only thing we can hope is that they deliver on the results, initiation of new trials and also revenue from current sales. Overall not at all a bad entry point for those who have never bought cris. Risky? yes for sure but given the low price......man the upside could be huge. Right now with correction mode small biotechs are being squeezed tight so we are left with low valuation for stocks like cris.
At this point in my opinion most investors probably feel that there is still time left for exiting stuff to happen here and are keeping off. The drop is most likely related to the exit of short time holders who jumped in hoping there will be a bounce after the release into the mid 2s. They are now clearing the house. I am still long with higher entry point but can definitely say that it is definitely one of the risky stocks at this point. The upside could be absolutely HUGE ($3.5 to 4 easily) but a drop to 1.6 on any setback to current trials is also a possibility. Those who are new here please dont buy into the $10 talk. Having said that $10 is possible but the chances are extremely remote given current information.
Sentiment: Strong Buy
not even worth $2???
I always ignored the irrational pumping that was going on for some time now here. Some said $10 soon!!!!! But even after ignoring all that noise shouldn't it be worth atleast $3?? Well i guess we just have to wait loooong.